TY - JOUR
T1 - Gene therapy for colorectal cancer: Therapeutic potential
AU - Chen, Ming-Jen
AU - Chung-Faye, Guy
AU - Searle, Peter
AU - Young, Lawrence
AU - Kerr, David
PY - 2001/1/1
Y1 - 2001/1/1
N2 - Colorectal cancer is a leading cause of cancer mortality in Western countries. Gene therapy has been proposed as a potential novel treatment modality for colorectal cancer, but it is still in an early stage of development. The preclinical data have been promising and numerous clinical trials are underway. This brief review aims to summarise the current status of clinical trials of different gene therapy strategies, including immune stimulation, mutant gene correction, prodrug activation and oncolytic virus therapy, for patients with colorectal cancer. Data from phase I trials have proven the safety of the reagents but have not yet demonstrated significant therapeutic benefit. In order to achieve this and extend the scope of the treatment, continuing efforts should be made to improve the antitumour potency, efficiency of gene delivery and accuracy of gene targeting.
AB - Colorectal cancer is a leading cause of cancer mortality in Western countries. Gene therapy has been proposed as a potential novel treatment modality for colorectal cancer, but it is still in an early stage of development. The preclinical data have been promising and numerous clinical trials are underway. This brief review aims to summarise the current status of clinical trials of different gene therapy strategies, including immune stimulation, mutant gene correction, prodrug activation and oncolytic virus therapy, for patients with colorectal cancer. Data from phase I trials have proven the safety of the reagents but have not yet demonstrated significant therapeutic benefit. In order to achieve this and extend the scope of the treatment, continuing efforts should be made to improve the antitumour potency, efficiency of gene delivery and accuracy of gene targeting.
UR - http://www.scopus.com/inward/record.url?scp=0034905663&partnerID=8YFLogxK
U2 - 10.2165/00063030-200115060-00002
DO - 10.2165/00063030-200115060-00002
M3 - Article
SN - 1173-8804
VL - 15
SP - 357
EP - 367
JO - BioDrugs
JF - BioDrugs
IS - 6
ER -